TrilynX
A promising phase 2 drug that sensitises tumours to radiation made things worse in phase 3, a reminder that early wins in this disease often do not replicate.
Terminated 24 June 2024 for futility at interim analysis; median EFS 19.4 months with xevinapant versus 33.1 with placebo (JCO 2025), attributed partly to toxicity and treatment interruptions. Followed a phase 2 with a striking OS benefit. Development of xevinapant was discontinued.
- Median 19.4 vs 33.1 months with Xevinapant + CRT compared with Placebo + CRT; about 13.7 months shorter for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Unresected locally advanced HNSCC: xevinapant + cisplatin chemoradiation vs placebo + chemoradiation. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
730 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Event-free survivalprimary | Xevinapant + CRT | — | 19.4 months | — | — | link |
| Placebo + CRT | — | 33.1 months |
Pages like this
not linked directly; found by shared links- TrialJAVELIN Head and Neck 100
Shares IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma and the tag failure.
- IdeaPhotobiomodulation and a taste and swallowing programme for mouth and throat toxicity
Shares IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma.
- ProductADU-S100 (MIW815)
Shares Head and neck squamous cell carcinoma and the tag failure.
- TrialOUTBACK / ANZGOG 0902 / GOG-0274
Shares IMRT / IGRT (modern external beam) and the tag failure.
- PersonJun Ma
Shares IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma.
- InstitutionUniversity of Malaya Medical Centre
Shares IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma.
- InstitutionHokkaido University Hospital
Shares IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma.
- TrialRTOG 0129 (HPV analysis)
Shares IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma.